Keyword: Singapore

Singapore's Tessa Therapeutics is ready fora commercial-scale facility to manufacture virus-specific T cell (VST) immunotherapies.

South Korean drugmaker gets a U.S. regulatory warning, new results in Takeda and Myovant’s trial for relugolix to treat uterine fibroids and more.

Takeda got FDA approval for Ariad-developed Alunbrig, WuXi NextCODE secured a $75 million Series B, and the FDA cited the third Dr. Reddy's plant this year.

The FDA scolded a Singapore maker of eye washes and other consumer products for poor manufacturing processes.

ASLAN just rolled out positive top-line phase 2 data for its lead drug candidate varlitinib when combined with chemotherapy for the treatment of HER2-positive breast cancer.

Novartis will shutter two Asian research facilities, but says Shanghai's position as third R&D hub alongside Basel and Cambridge is secure.

ASLAN Pharmaceuticals received $10 million from Bristol-Myers Squibb in a deal that saw the multinational reacquire rights to gastric cancer candidate ASLAN002 that has completed Phase I work.

Singapore's ASLAN Pharmaceutical has moved to bring along its first mAb candidate, ASLAN004, by working with Selexis of Switzerland.

ASLAN Pharmaceuticals has raised $23 million from existing and new investors as it gears up for an expected initial public offering with a Phase II underway for pan-HER inhibitor varlitinib.

ASLAN Pharmaceuticals said its pan-HER inhibitor varlitinib (ASLAN001) has received a U.S. FDA orphan designation for a second indication in gastric cancer.